NCT02273596 - Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 24, 2014

Primary Completion Date

October 27, 2016

Study Completion Date

November 7, 2018

Conditions

Wilson Disease

Interventions

DRUG

ALXN1840

Individualized oral doses of ALXN1840.

Trial Locations (9)

Clinical Trial Site, Vienna

Clinical Trial Site, Ann Arbor

Clinical Trial Site, Chicago

Clinical Trial Site, Heidelberg

Clinical Trial Site, Los Angeles

Clinical Trial Site, New Haven

Clinical Trial Site, Warsaw

Clinical Trial Site, Guildford

Clinical Trial Site, Birmingham